Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in childhood
A double-blind, placebo-controlled trial in 93 children, aged 6-15 years, and with functional abdominal pain (Rome III criteria). The interventions were a chewable tablet with L. reuteri DSM 17938 at a dose of 10^8 cfu/day (n=47) or the equivalent placebo tablet (n=46), once daily. The intervention period was 4 weeks, with follow-up after another 4 weeks. The primary endpoints were frequency and intensity of abdominal pain.
Significant relief in frequency (p<0.02) and severity (p<0.01) of abdominal pain compared to placebo at 4 weeks. Continuously and significantly relieved severity of abdominal pain compared to placebo at 8 weeks. Reduced incidence of perceived abdominal distension and bloating compared to placebo at 4 weeks (p=0.013).
L. reuteri Protectis significantly reduced the frequency and severity of functional abdominal pain in children.
Weizman Z, Abu-Abed J, Binsztok M. Lactobacillus reuteri DSM 17938 for the management of functional abdominal pain in childhood: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2016;174:160-164.